Prediction of coronary heart disease using risk factor categories

Circulation

Volumn 97, Issue 18, 1998, Pages 1837-1847

  Wilson, Peter W F ^a   D'Agostino, Ralph B ^b   Levy, Daniel ^a   Belanger, Albert M ^b   Silbershatz, Haut ^b   Kannel, William B ^c  

^a FRAMINGHAM HEART STUDY   (United States)

^b Boston University   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cholesterol; Coronary disease; Hypertension; Prediction

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ALGORITHM; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; SEX DIFFERENCE;

EID: 0032510639     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.97.18.1837     Document Type: Article

References (66)

1. McGovern PG, Pankow JS, Shahar E, Doliszny KM, Folsom AR, Blackburn H, Luepker RV. the Minnesota Heart Survey Investigators. Recent trends in acute coronary heart disease: mortality, morbidity, medical care, and risk factors. N Engl J Med. 1996;334:884-890.
2. Gordon T, Kannel WB. Multiple risk functions for predicting coronary heart disease: the concept, accuracy, and application. Am Heart J. 1982; 103:1031-1039.
3. Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham Study. Diabetes Care. 1979;2:120-126.
4. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. Diabetes, blood lipids, and the role of obesity in coronary heart disease risk for women. Ann Intern Med. 1977;87:393-397.
5. The Expert Panel. Report of the National Cholesterol Education Program Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med. 1988;34:193-201.
6. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel II). JAMA. 1993;269:3015-3023.
7. The Expert Panel. National Cholesterol Education Program Second Report. The expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel u). Circulation. 1994;89:1333-1445.
8. Anderson KM, Odell PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293-298.
9. The Expert Panel. Expert panel on detection, evaluation and treatment of high blood cholesterol in adults: summary of the second report of the NCEP expert panel (Adult Treatment Panel II). JAMA. 1993;269: 3015-3023.
10. Joint National Committee. The fifth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC V). Arch Intern Med. 1993;153:154-183.
11. Anderson KM, Wilson PWF, Odell PM, Kannel WB. An updated coronary risk profile: a statement for health professionals. Circulation. 1991; 83:357-363.
12. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: the Framingham Offspring Study. Am J Epidemiol. 1979:110:281-290.
13. Abell LL, Levy BB, Brodie BB, Kendall FE. A simplified method for the estimation of total cholesterol in serum and demonstration of its specificity. J Biol Chem. 1952;195:357-366.
14. Lipid Research Clinics Program. Manual of Laboratory Operation, Bethesda, Md: National Institutes of Health; 1974:75-628.
15. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
16. Manual of Laboratory Operations: Lipid Research Clinics Program, Lipid and Lipoprotein Analysis. Washington, DC: National Institutes of Health, US Department of Health and Human Services; 1982.
17. Kannel WB, Wolf PA, Garrison RJ. Monograph Section 34: Some Risk Factors Related to the Annual Incidence of Cardiovascular Disease and Death Using Pooled Repeated Biennial Measurements: Framingham Heart Study, 30-Year Followup. Springfield, Mass: National Technical Information Service; 1987:1-459.
18. Neter J, Wasserman W. Multiple regression. In: Applied Linear Statistical Models. Homewood, Ill: Irwin; 1974:214-272.
19. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34: 187-220.
20. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387.
21. Benfante R, Reed D. Is elevated serum cholesterol level a risk factor for coronary heart disease in the elderly? JAMA. 1990;263:393-396.
22. Wilson PWF, Castelli WP, Kannel WB. Coronary risk prediction in adults: the Framingham Heart Study. Am J Cardiol. 1987;59:91-94.
23. Corti MC, Guralnik JM, Salive ME, Harris T, Field TS, Wallace RB, Berkman LF, Seeman TE, Glynn RJ, Hennekens CH, Havlik RJ. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA. 1995;274:539-544.
24. Wilson PWF, Kannel WB. Hypercholesterolemia and coronary risk in the elderly: the Framingham Study. Am J Geriat Cardiol, 1993;2:52-56.
25. McNamara JR, Cohn JS, Wilson PWF, Schaefer EJ. Calculated values for low-density lipoprotein cholesterol in the assessment of lipid abnormalities and coronary disease risk. Clin Chem. 1990;36:36-42.
26. McNamara JR, Cole TG, Contois JH, Ferguson CA, Ordovas JM, Schaefer EJ. Immunoseparation method for measuring low-density lipoprotein cholesterol directly from serum evaluated. Clin Chem. 1995; 41:232-240.
27. National Education Programs Working Group report on the management of patients with hypertension and high blood cholesterol. Ann Intern Med. 1991;114:224-237.
28. Graver SA, Abrahamowicz M, Joseph L, Brewer C, Coupai L, Suissa S. The benefits of treating hyperlipidemia to prevent coronary heart disease: estimating changes in life expectancy and morbidity. JAMA. 1992;267:816-822.
29. Grover SA, Coupai L, Hu XP. Identifying adults at increased risk of coronary disease: how well do the current cholesterol guidelines work? JAMA. 1995;274:801-806.
30. Levy D. Have expert panel guidelines kept pace with new concepts in hypertension? Lancet. 1995;346:1112.
31. Cooper GR, Myers GL, Smith J, Schlant RC. Blood lipid measurements: variations and practical utility. JAMA. 1992;267:1652-1660.
32. Wilson PWF. Cholesterol screening: once is not enough. Arch Intern Med. 1995;155:2146-2147.
33. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
34. The 4S Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
35. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ, West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
36. Myers RH, Kiely DK, Cupples LA, Kannel WB. Parental history is an independent risk factor for coronary artery disease: the Framingham Study. Am Heart J. 1990;120:963-969.
37. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a metaanalysis and review of the literature. Ann Intern Med. 1993;118:956-963.
38. Kannel WB, Wolf R, Castelli WP, D'Agostino RB. Fibrinogen and risk of cardiovascular disease: the Framingham Study. JAMA. 1987;258:1183-1186.
39. Kannel WB, D'Agostino RB, Wilson PWF, Belanger AJ, Gagnon DR. Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J. 1990;120:672-676.
40. Barasch E, Benderly M, Graff E, Behar S, Reicher-Reiss H, Caspi A, Pelled B, Reisin L, Roguin N, Goldbourt U. Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients: the Bezafibrate Infarction Prevention (BIP) Study. J Clin Epidemiol. 1995;48:757-765.
41. Pasley BH, Standfast SJ, Katz SH. Prescribing estrogen during menopause: physician survey of practices in 1974 and 1981. Public Health Rep. 1984;99:424-429.
42. Bush TL, Cowan LD, Barrett-Connor EL, Criqui MH, Karon JM, Wallace RB, Tyroler HA, Rifkind BM. Estrogen use and all-cause mortality. JAMA. 1983;249:903-906.
43. Barrett-Connor EL, Bush TL. Estrogen and coronary heart disease in women. JAMA. 1991;265:1861-1867.
44. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease: ten-year follow-up from the Nurses' Health Study. N Engt J Med. 1991;325:756-762.
45. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: quantitative assessment of the epidemiologic evidence. Prev Med. 1991;20:47-63.
46. Wilson PWF, Garrison RJ, Castelli WP. Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity: the Framingham Study. N Engl J Med. 1985;313:1038-1043.
47. Eaker ED, Castelli WP. Coronary heart disease and its risk factors among women in the Framingham Study. In: Eaker ED, Packard B, Wenger NK, Clarkson TB, Tyroler HA, eds. Coronary Heart Disease in Women. New York, NY: Haymarket Doyma Inc; 1987:122-130.
48. Petitti DB, Reporting results. In: Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis. New York, NY: Oxford; 1994:197-211.
49. Powell KE, Thompson PD, Caspersen CJ, Kendrick JS. Physical activity and the incidence of coronary heart disease. Anna Rev Public Health. 1987;8:253-287.
50. Lee IM, Hsieh CC, Paffenbarger RS Jr. Exercise intensity and longevity in men: the Harvard Alumni Health Study. JAMA. 1995;273:1179-1184.
51. Berlin JA, Colditz GA. A meta-analysis of physical activity in the prevention of coronary heart disease. Am J Epidemiol. 1990;132:612-628.
52. Wilson PWF. High-density lipoprotein, low-density lipoprotein and coronary artery disease. Am J Cardiol. 1990;66(suppl A):7-10.
53. Anderson KM, Wilson PWF, Garrison RJ, Castelli WP. Longitudinal and secular trends in lipoprotein cholesterol measurements in a general population sample: the Framingham Offspring Study. Atherosclerosis. 1987;68:59-66.
54. Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS Jr. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med. 1991;325:147-152.
55. Burchfiel CM, Curb JD, Sharp DS, Rodriguez BL, Arakaki R, Chyou PH, Yano K. Distribution and correlates of insulin in elderly men: the Honolulu Heart Program. Arterioscler Thromb Vasc Biol. 1995;15:2213-2221.
56. Wood PD. Physical activity, diet, and health: independent and interactive effects. Med Sci Sports Exerc. 1994;26:838-843.
57. Dannenberg AL, Keller JB, Wilson PWF, Castelli WP. Leisure time physical activity in the Framingham Offspring Study: description, seasonal variation, and risk factor correlates. Am J Epidemiol. 1989;129:76-87.
58. Wood PD, Haskell WL, Klein H, Lewis S, Stern MP, Farquhar JW. The distribution of plasma lipoproteins in middle-aged male runners. Metabolism. 1976;25:1249-1257.
59. Gordon T, Garcia-Palmieri MR, Kagan A, Kannel WB, Schiffman J. Differences in coronary heart disease in Framingham, Honolulu and Puerto Rico. J Chronic Dis. 1974;27:329-344.
60. McGee D, T Gordon. The Framingham Study applied to four other U. S. based epidemiological studies of cardiovascular disease (Section No. 31). Bethesda, Md: US Department of Health, Education, and Welfare, NIH; 1976:76-1083.
61. Brand RJ, Rosenman RH, Scholtz RI. Multivariate prediction of coronary heart disease in the Western Collaborative Group Study compared to the findings of the Framingham Study. Circulation. 1976;53:348-355.
62. Leaverton PE, Sortie PD, Kleinman JC, Dannenberg AL, Ingster-Moore L, Kannel WB, Cornoni-Huntley JC. Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study. J Chronic Dis. 1987;40:775-784.
63. The Multiple Risk Factor Intervention Trial Group. Statistical design considerations in the NHLI multiple risk factor intervention trial (MRFIT). J Chronic Dis. 1977;30:261-275.
64. Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin DM, Payne JN. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet. 1996;348:387-388.
65. Wesl of Scotland Coronary Prevention Group. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet. 1996;348:1339-1342.
66. Kinosian B, Click H, Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann Intern Med. 1994;121:641-647.